Nutriband Inc. Registers New Company Branch in Ecuador with Plans to Expand into the South American Market

Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB, NASDAQ:NTRBW) has announced the opening of a new branch in Quito, Ecuador, aimed at expanding its product offerings in the region through product registration and contract services. CEO Gareth Sheridan emphasized this move as a significant step towards enhancing revenue opportunities and building relationships. The company specializes in developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing AVERSA® technology. This expansion marks a strategic initiative to penetrate the South American market.

Positive

• Opening of a new branch in Quito, Ecuador.
• Expansion of product offerings through registration and contract services.
• Focus on enhancing revenue opportunities and building relationships in new markets.

Negative

• None.

ORLANDO, FL / ACCESSWIRE / July 22, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) is pleased to announce the opening of its new branch in Quito, Ecuador. The Company plans to expand its product offering to the region through product registration and contract services.

‘This is a key step for Nutriband and our shareholders as it shows our commitment to expanding our offerings into new markets with a goal to continue to build our revenue opportunities and relationships' said Gareth Sheridan, CEO.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA® technology. Aversa is an abuse deterrent transdermal technology that incorporates aversive agents to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential, specifically opioids.

The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes,'' "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2022 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

For more information, contact:

Investor Relations
RedChip Companies
Dave Gentry
Dave@redchip.com
1-800-RED-CHIP (733-2447)
407-491-4498

SOURCE: Nutriband, Inc.

View source version on accesswire.com:
https://www.accesswire.com/709464/Nutriband-Inc-Registers-New-Company-Branch-in-Ecuador-with-Plans-to-Expand-into-the-South-American-Market

FAQ

What is the significance of Nutriband's new branch in Ecuador?

The new branch in Quito, Ecuador, represents Nutriband's commitment to expanding its market presence and revenue opportunities in South America.

What products is Nutriband focusing on in Ecuador?

Nutriband is focusing on its transdermal pharmaceutical products, particularly the abuse deterrent fentanyl patch using AVERSA® technology.

What are the stock symbols for Nutriband?

Nutriband trades under the stock symbols NASDAQ:NTRB and NASDAQ:NTRBW.

Who is leading Nutriband and what did they say about the expansion?

CEO Gareth Sheridan stated that the Ecuador branch is a key step in building revenue opportunities and relationships.